PAR 5.00% 19.0¢ paradigm biopharmaceuticals limited..

Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-118

  1. 9,839 Posts.
    lightbulb Created with Sketch. 1258
    If the science itself makes it a large commercial opportunity it does NOT make sense for Pharma/VC/ Other parties not to engage.

    They aren't just sitting around waiting to pick the remains off a dead carcass.

    PAR inexperience in how and when to strike a deal is the real issue and NOT whether anyone was interested




    Last edited by Denial: 01/02/24
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.